Difference between revisions of "Tegafur, gimeracil, oteracil (S-1)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 12: Line 12:
 
*[[Pancreatic cancer]]
 
*[[Pancreatic cancer]]
 
*[[Rectal cancer]]
 
*[[Rectal cancer]]
 +
 +
==History of changes in EMA indication==
 +
*3/14/2011: Initial marketing authorization as Teysuno.
  
 
==Also known as==
 
==Also known as==
 
*'''Code name:''' S-1
 
*'''Code name:''' S-1
*'''Brand name:''' Teysuno
+
*'''Brand name:''' Teysuno, TS-One
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]
Line 30: Line 33:
 
[[Category:Rectal cancer medications]]
 
[[Category:Rectal cancer medications]]
  
[[Category:EMA approved drugs]]
+
[[Category:EMA approved in 2011]]
 
[[Category:PMDA approved drugs]]
 
[[Category:PMDA approved drugs]]

Revision as of 16:36, 4 December 2021

Note: this drug is approved in Japan and Europe but not the US. References will be gradually added.

Mechanism of action

From the NCI Drug Dictionary: An orally bioavailable fluoropyrimidine antagonist composed of tegafur combined with two modulators of 5-flurouracil (5-FU) activity, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur is a prodrug of 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, DNA synthesis and cell division, and competes with uridine triphosphate, thus inhibiting RNA and protein synthesis. CDHP is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Potassium oxonate preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), thereby decreasing activation of 5-FU in the gut and activated 5-FU-related gastrointestinal toxicity.

Diseases for which it is used

History of changes in EMA indication

  • 3/14/2011: Initial marketing authorization as Teysuno.

Also known as

  • Code name: S-1
  • Brand name: Teysuno, TS-One